Table of contents

Nephrogenic systemic fibrosis


Key sources

The following summarized guidelines for the evaluation and management of nephrogenic systemic fibrosis are prepared by our editorial team based on guidelines from the European Academy of Dermatology and Venereology (EADV 2017). ...
Show more

Screening and diagnosis

Etiology: as per EADV 2017 guidelines, recognize that nephrogenic systemic fibrosis is an iatrogenic condition observed in patients with end-stage renal failure and is associated with gadolinium exposure.
Create free account

Medical management

Medical therapy: as per EADV 2017 guidelines, insufficient evidence to recommend any treatment in patients with nephrogenic systemic fibrosis.

Preventative measures

Avoidance of gadolinium-containing contrast agents
As per EADV 2017 guidelines:
Avoid using high-risk gadolinium-based contrast agents, especially in patients with an eGFR of < 30 mL/min, for the prevention of nephrogenic systemic fibrosis.
Use a low-risk gadolinium medium and reduce the dose of the gadolinium-based contrast agents to the minimum effective dosage for imaging if MRI with gadolinium-based contrast agents is indispensable.

More topics in this section

  • Dialysis